Fierce Biotech

Rivia launches AI-powered clinical trial data review module, with Scancell as early adopter

Swiss data engine Rivia has launched a new AI-powered data review module to speed up clinical data cleaning. | Swiss data ...
Fierce Biotech

AstraZeneca buys partner Omniose for bacterial vaccine technology

AstraZeneca has acquired vaccine bioconjugation specialist Omn | AstraZeneca has acquired vaccine bioconjugation specialist ...
Fierce Biotech

Beam’s sickle cell therapy results tee up potential Casgevy, Lyfgenia showdown

Gearing up for a potential FDA filing by the end of the year, Beam Therapeutics revealed results from a phase 1/2 study of ...
Fierce Biotech

Mirum scores again in hepatitis D phase 3, setting the stage for brelovitug’s FDA run

Mirum Pharmaceuticals has kept its clinical winning streak alive in hepatitis D, meeting the primary endpoint in another late ...
Fierce Biotech

PepGen’s stock doubles as midphase muscle dystrophy data wow analysts

PepGen’s phase 2 myotonic dystrophy type 1 (DM1) data have met analysts’ best-case scenario, causing the biotech’s share ...
Fierce Biotech

AbCellera becomes latest biotech to abandon dream of developing OX40 drug

AbCellera has become the latest drug developer to abandon its attempts to crack the OX40 code. | AbCellera has become the ...
Fierce Biotech

Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from China

Windward Bio is sailing toward the public markets with the aim of wafting in over $200 million in proceeds to fund two ...